Business Model Breakdown
How Resmed Inc Makes Money
RMD
Market Cap
$32.6B
Annual Revenue
$5.1B
Profit Margin
0.0%
The Short Version
ResMed Inc. designs, manufactures, and markets medical devices and software solutions for the diagnosis, treatment, and management of sleep-disordered breathing (like sleep apnea) and other respiratory conditions (like COPD). The company generates revenue primarily through the sale of its masks, accessories, and flow generators (CPAP, BiPAP devices), complemented by growing subscription revenue from its digital health software platforms that allow remote patient monitoring and data management for healthcare providers.
Where the Revenue Comes From
Device Sales (e.g., CPAP/BiPAP machines)
Masks & Accessories Sales (recurring consumables)
Software & Service Subscriptions (connected health platforms)
Who buys: Primarily healthcare providers (hospitals, sleep labs), home medical equipment (HME) providers, and to a lesser extent, direct-to-consumer sales for patients.
Why It Works (Competitive Advantages)
- ✔Strong brand recognition and reputation in sleep and respiratory care
- ✔Extensive intellectual property portfolio and R&D capabilities
- ✔Global distribution network and established clinician relationships
- ✔Integrated digital health ecosystem (connected devices, software)
Economic Moat: Narrow (Brand Power, Switching Costs, Intangible Assets/IP, Efficient Scale)
What Our Analysis Says
DVR Score as of April 6, 2026
ResMed Inc. (RMD) remains a robust, highly profitable, and well-managed global leader in sleep apnea and respiratory care. Its Q2 fiscal 2026 results showed healthy 11% YoY revenue growth and strong margins, with a very solid balance sheet. However, this analysis specifically targets '10x growth potential within the next 3-5 years.' Given RMD's current large-cap status ($32.64B), achieving a market capitalization exceeding $320 billion in such a timeframe is extraordinarily improbable. The company operates in established healthcare sectors characterized by steady, incremental growth rather than exponential expansion. No material changes or revolutionary catalysts have emerged since the last analysis 17 days ago that would realistically alter RMD's fundamental growth trajectory to support hyper-growth. While a sound investment for stable growth, it does not align with our hyper-growth criteria.